Pfizer (PFE) : Marble Harbor Investment Counsel scooped up 335 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 3, 2016. The investment management firm now holds a total of 368,945 shares of Pfizer which is valued at $12,389,173.Pfizer makes up approximately 3.13% of Marble Harbor Investment Counsel’s portfolio.
Other Hedge Funds, Including , Motco boosted its stake in PFE in the latest quarter, The investment management firm added 96 additional shares and now holds a total of 107,523 shares of Pfizer which is valued at $3,610,622. Pfizer makes up approx 0.43% of Motco’s portfolio.Liberty Capital Management boosted its stake in PFE in the latest quarter, The investment management firm added 3,550 additional shares and now holds a total of 11,769 shares of Pfizer which is valued at $384,964. Pfizer makes up approx 0.30% of Liberty Capital Management’s portfolio.Hl Financial Services boosted its stake in PFE in the latest quarter, The investment management firm added 114,660 additional shares and now holds a total of 2,815,785 shares of Pfizer which is valued at $92,104,327. Pfizer makes up approx 2.24% of Hl Financial Services’s portfolio.Hills Bank Trust Co boosted its stake in PFE in the latest quarter, The investment management firm added 9,120 additional shares and now holds a total of 19,485 shares of Pfizer which is valued at $637,354. Pfizer makes up approx 0.23% of Hills Bank Trust Co’s portfolio.Joel Isaacson reduced its stake in PFE by selling 762 shares or 1.94% in the most recent quarter. The Hedge Fund company now holds 38,583 shares of PFE which is valued at $1,283,656. Pfizer makes up approx 0.28% of Joel Isaacson’s portfolio.
Pfizer closed down -0.02 points or -0.06% at $33.8 with 2,47,87,046 shares getting traded on Tuesday. Post opening the session at $33.83, the shares hit an intraday low of $33.48 and an intraday high of $33.87 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.
Many Wall Street Analysts have commented on Pfizer. Company shares were Reiterated by UBS on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $36 .Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.